NuCana PLC
NASDAQ:NCNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NuCana PLC
Common Shares Outstanding
NuCana PLC
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NuCana PLC
NASDAQ:NCNA
|
Common Shares Outstanding
£20.8B
|
CAGR 3-Years
635%
|
CAGR 5-Years
233%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Common Shares Outstanding
£50.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Common Shares Outstanding
$96.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Common Shares Outstanding
£66.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Common Shares Outstanding
£120.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Niox Group PLC
LSE:NIOX
|
Common Shares Outstanding
£417.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
NuCana PLC
Glance View
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.
See Also
What is NuCana PLC's Common Shares Outstanding?
Common Shares Outstanding
20.8B
GBP
Based on the financial report for Dec 31, 2025, NuCana PLC's Common Shares Outstanding amounts to 20.8B GBP.
What is NuCana PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
233%
Over the last year, the Common Shares Outstanding growth was 14 551%. The average annual Common Shares Outstanding growth rates for NuCana PLC have been 635% over the past three years , 233% over the past five years .
